[
  {
    "ts": null,
    "headline": "Gilead Prices $3.5 Billion of Senior Unsecured Notes",
    "summary": "Gilead Sciences, Inc. , a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, today announced the pricing of senior unsecured notes in an...",
    "url": "https://finnhub.io/api/news?id=4fa574fb0cd335c5bcc7ecc977896161659a6eb43cb8d8e5b772a17e91332b47",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731529503,
      "headline": "Gilead Prices $3.5 Billion of Senior Unsecured Notes",
      "id": 131337181,
      "image": "",
      "related": "GILD",
      "source": "Finnhub",
      "summary": "Gilead Sciences, Inc. , a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, today announced the pricing of senior unsecured notes in an...",
      "url": "https://finnhub.io/api/news?id=4fa574fb0cd335c5bcc7ecc977896161659a6eb43cb8d8e5b772a17e91332b47"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences' (NASDAQ:GILD) Soft Earnings Are Actually Better Than They Appear",
    "summary": "Gilead Sciences, Inc.'s ( NASDAQ:GILD ) stock was strong despite it releasing a soft earnings report last week...",
    "url": "https://finnhub.io/api/news?id=266c703ea5ac69b1475e066bd0c7281790130797d6b3cb6c0e8149d02140ba34",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731523504,
      "headline": "Gilead Sciences' (NASDAQ:GILD) Soft Earnings Are Actually Better Than They Appear",
      "id": 131330752,
      "image": "",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead Sciences, Inc.'s ( NASDAQ:GILD ) stock was strong despite it releasing a soft earnings report last week...",
      "url": "https://finnhub.io/api/news?id=266c703ea5ac69b1475e066bd0c7281790130797d6b3cb6c0e8149d02140ba34"
    }
  },
  {
    "ts": null,
    "headline": "Gilead data lends insight into transforming HIV prevention landscape",
    "summary": "New clinical trial findings show that twice-yearly lenacapavir for HIV pre-exposure prophylaxis had high efficacy and safety in a diverse group of participants.This data provides the first in-depth...",
    "url": "https://finnhub.io/api/news?id=39626592fd1fdc6f27ea7984db33e76104a1d857d4e8d85e611c332e24a18fe9",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731519900,
      "headline": "Gilead data lends insight into transforming HIV prevention landscape",
      "id": 131335573,
      "image": "",
      "related": "GILD",
      "source": "Finnhub",
      "summary": "New clinical trial findings show that twice-yearly lenacapavir for HIV pre-exposure prophylaxis had high efficacy and safety in a diverse group of participants.This data provides the first in-depth...",
      "url": "https://finnhub.io/api/news?id=39626592fd1fdc6f27ea7984db33e76104a1d857d4e8d85e611c332e24a18fe9"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences Inc. stock underperforms Wednesday when compared to competitors",
    "summary": "Gilead Sciences Inc. stock underperforms Wednesday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=da786011a3cf460823bca785e0a48cec591beff670a8b0a3443ae07a2315a130",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731516060,
      "headline": "Gilead Sciences Inc. stock underperforms Wednesday when compared to competitors",
      "id": 131417144,
      "image": "",
      "related": "GILD",
      "source": "MarketWatch",
      "summary": "Gilead Sciences Inc. stock underperforms Wednesday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=da786011a3cf460823bca785e0a48cec591beff670a8b0a3443ae07a2315a130"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Presents Full PURPOSE 2 Data Results for Twice-Yearly Lenacapavir for HIV Prevention at HIV Glasgow",
    "summary": "FOSTER CITY, Calif., November 13, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE 2 trial (NCT04925752), which is studying twice-yearly lenacapavir, the company’s injectable HIV-1 capsid inhibitor, for the investigational use of HIV prevention among a broad and geographically diverse range of cisgender men and gender-diverse people. Newly presented results include data on adherence to and pharmacokinetics of lena",
    "url": "https://finnhub.io/api/news?id=64decd4706d231994c2d81e30201c84702cfbad707d9c02753dcecc0c3e6d661",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731498300,
      "headline": "Gilead Presents Full PURPOSE 2 Data Results for Twice-Yearly Lenacapavir for HIV Prevention at HIV Glasgow",
      "id": 131330756,
      "image": "https://s.yimg.com/ny/api/res/1.2/Ad0CRtCpmRmPqItykStPYA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD00MDA-/https://media.zenfs.com/en/business-wire.com/3a2c2de8a29149488f8202ba9ed9565a",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "FOSTER CITY, Calif., November 13, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE 2 trial (NCT04925752), which is studying twice-yearly lenacapavir, the company’s injectable HIV-1 capsid inhibitor, for the investigational use of HIV prevention among a broad and geographically diverse range of cisgender men and gender-diverse people. Newly presented results include data on adherence to and pharmacokinetics of lena",
      "url": "https://finnhub.io/api/news?id=64decd4706d231994c2d81e30201c84702cfbad707d9c02753dcecc0c3e6d661"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences, Inc. - Scientific Leadership Spotlighted as Gilead Presents Research Data across Its Broad and Innovative HIV Treatment Portfolio and Pipeline",
    "summary": "FOSTER CITY - Gilead Sciences, Inc. today announced the presentation of new research data from its innovative HIV treatment portfolio and pipeline, including a broad range of data on investigational...",
    "url": "https://finnhub.io/api/news?id=86fa629e7ed2677fd30bf3e084eee10563a81efafe70aaa4b000927215bd58f6",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731493174,
      "headline": "Gilead Sciences, Inc. - Scientific Leadership Spotlighted as Gilead Presents Research Data across Its Broad and Innovative HIV Treatment Portfolio and Pipeline",
      "id": 131325330,
      "image": "",
      "related": "GILD",
      "source": "Finnhub",
      "summary": "FOSTER CITY - Gilead Sciences, Inc. today announced the presentation of new research data from its innovative HIV treatment portfolio and pipeline, including a broad range of data on investigational...",
      "url": "https://finnhub.io/api/news?id=86fa629e7ed2677fd30bf3e084eee10563a81efafe70aaa4b000927215bd58f6"
    }
  },
  {
    "ts": null,
    "headline": "Decoding Gilead Sciences Inc (GILD): A Strategic SWOT Insight",
    "summary": "Insightful Analysis of Gilead Sciences Inc's Financial Health and Market Position",
    "url": "https://finnhub.io/api/news?id=e7ebae61fc3546932775db9c39c3581a0cd45075c3c2a690ca8ebdeb115e0eae",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731474252,
      "headline": "Decoding Gilead Sciences Inc (GILD): A Strategic SWOT Insight",
      "id": 131330762,
      "image": "https://media.zenfs.com/en/us.finance.gurufocus/84a579dd14fa3db57968682e27407e42",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Insightful Analysis of Gilead Sciences Inc's Financial Health and Market Position",
      "url": "https://finnhub.io/api/news?id=e7ebae61fc3546932775db9c39c3581a0cd45075c3c2a690ca8ebdeb115e0eae"
    }
  }
]